Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Chronic Obstructive Pulmonary Disease-II: Pathophysiology

Chronic Obstructive Pulmonary Disease-II: Pathophysiology

Chronic Obstructive Pulmonary Disease (COPD) pathophysiology is intricate and multifaceted, involving a complex interplay of physiological processes. Understanding these mechanisms is crucial for effectively managing and treating COPD. Here is an in-depth look at the critical elements in the pathophysiology of COPD:
Chronic Inflammation

Chronic Obstructive Pulmonary Disease II: Emphysema

Chronic Obstructive Pulmonary Disease II: Emphysema

Emphysema, a major phenotype of chronic obstructive pulmonary disease (COPD), is characterized by irreversible destruction of alveolar walls and permanent enlargement of distal airspaces. Unlike chronic bronchitis, which primarily affects the airways, emphysema predominantly involves the lung parenchyma, where structural damage leads to airflow limitation.PathophysiologyIt most commonly results from prolonged exposure to cigarette smoke and other toxic gases, particularly cigarette smoke.

Chronic Obstructive Pulmonary Disease

Chronic Obstructive Pulmonary Disease

COPD is defined as a heterogeneous lung condition marked by persistent respiratory symptoms such as dyspnea, cough, and sputum production, caused by abnormalities in the airways that cause airflow obstruction.
Smoking is a primary risk factor for COPD, with over 80% of patients having a history of it. Patients typically experience progressive dyspnea or labored breathing, frequent coughing, and recurrent pulmonary infections. Many eventually succumb to respiratory failure, characterized by...

COPD: Pathogenesis and Clinical Features

COPD: Pathogenesis and Clinical Features

Chronic obstructive pulmonary disease (COPD) is a group of lung conditions that progressively worsen over time, including chronic bronchitis and emphysema. This cluster of diseases collectively leads to a gradual and irreversible decline in lung function over time.
The primary cause for the onset of COPD is cigarette smoking and exposure to air pollution. These hazardous factors initiate a chain reaction within the lungs, resulting in chronic inflammation, damage to the airways, and a...

Chronic Obstructive Pulmonary Disease-I: Introduction

Chronic Obstructive Pulmonary Disease-I: Introduction

Chronic Obstructive Pulmonary Disease (COPD) is a long-lasting respiratory condition requiring continuous attention and care. It is a progressive lung disease that leads to breathing challenges due to airflow obstruction. It manifests as persistent respiratory symptoms and restricted airflow resulting from abnormalities in the airways and alveoli, usually due to long-term exposure to harmful particles or gases. COPD mainly consists of two primary conditions: emphysema and chronic bronchitis.

Chronic Obstructive Pulmonary Disease III: Chronic Bronchitis Features

Chronic Obstructive Pulmonary Disease III: Chronic Bronchitis Features

Chronic bronchitis is a key phenotype of chronic obstructive pulmonary disease (COPD), characterized by airway-centered inflammation and mucus overproduction. It develops from long-term exposure to harmful particles or gases, most commonly cigarette smoke, which triggers a persistent inflammatory response.Cellular and Structural ChangesInflammation initially affects the large bronchi and later the smaller airways, with infiltration by immune cells, including neutrophils, macrophages, and...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Continued Nintedanib Treatment in Children and Adolescents With Fibrosing ILDs: Data From InPedILD-ON.

Pediatric pulmonology·2026

Same author

Nintedanib in Post-COVID Interstitial Lung Disease: a double-blind, randomized, placebo-controlled Clinical Trial.

Annals of the American Thoracic Society·2026

Same author

Rheumatoid arthritis-associated interstitial lung disease: screening, diagnosis, and treatment-an expert group consensus statement.

The Lancet. Respiratory medicine·2026

Same author

Workplace Productivity Loss in Patients with Progressive Pulmonary Fibrosis: Data from the ILD-PRO Registry.

Lung·2026

Same author

Idiopathic pulmonary fibrosis risk loci in East Asian populations mirror those of European populations.

American journal of respiratory and critical care medicine·2026

Same author

Hospitalisations in patients with idiopathic pulmonary fibrosis: insights from the IPF-PRO Registry and EMPIRE Registry.

ERJ open research·2026

Search research articles

Related Experiment Video

Updated: May 17, 2026

Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease

Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease

Published on: June 16, 2020

Connective tissue disease-associated lung disease.

Amy L Olson¹, Kevin K Brown, Aryeh Fischer

¹Autoimmune and Interstitial Lung Disease Program, National Jewish Health, 1400 Jackson Street, Denver, CO 80206, USA.

Immunology and Allergy Clinics of North America

|October 30, 2012

Summary

Connective tissue diseases (CTDs) frequently impact the lungs, causing various pulmonary manifestations. Comprehensive patient assessment is crucial for managing respiratory symptoms and interstitial lung disease in CTDs.

More Related Videos

Primary Sjogren's Syndrome Associated with Lung Adenocarcinoma: Probing the Potential Common Pathogenic Mechanisms and Experimental Verification

Primary Sjogren's Syndrome Associated with Lung Adenocarcinoma: Probing the Potential Common Pathogenic Mechanisms and Experimental Verification

Published on: September 20, 2024

Related Experiment Videos

Last Updated: May 17, 2026

Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease

Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease

Published on: June 16, 2020

Primary Sjogren's Syndrome Associated with Lung Adenocarcinoma: Probing the Potential Common Pathogenic Mechanisms and Experimental Verification

Primary Sjogren's Syndrome Associated with Lung Adenocarcinoma: Probing the Potential Common Pathogenic Mechanisms and Experimental Verification

Published on: September 20, 2024

Area of Science:

Pulmonology
Rheumatology
Internal Medicine

Background:

Connective tissue diseases (CTDs) encompass a group of autoimmune disorders affecting multiple organ systems.
Pulmonary involvement is a significant cause of morbidity and mortality in patients with CTDs.
Understanding the spectrum of lung complications is vital for effective patient management.

Purpose of the Study:

To provide a comprehensive overview of the pulmonary manifestations associated with various CTDs.
To highlight the importance of thorough respiratory assessment in patients diagnosed with CTDs.
To emphasize CTD-associated interstitial lung disease (CTD-ILD) as a key area of concern.

Main Methods:

Literature review of existing studies and clinical guidelines on CTDs and pulmonary complications.
Synthesis of information regarding direct and indirect pulmonary manifestations across different CTDs.
Focus on the diagnostic and management considerations for CTD-ILD.

Main Results:

CTDs present with a wide range of pulmonary issues, including interstitial lung disease, pulmonary hypertension, and airway diseases.
Indirect complications like infections and drug toxicity also contribute to respiratory problems in CTD patients.
CTD-ILD is a prevalent and serious complication requiring specific diagnostic and therapeutic approaches.

Conclusions:

Pulmonary manifestations are common and diverse in CTDs, necessitating a high index of suspicion.
Integrated care involving pulmonologists and rheumatologists is essential for optimal outcomes.
Early recognition and management of CTD-associated lung disease, particularly ILD, can improve patient prognosis.